Latest News and Press Releases

Study’s primary endpoint and key secondary endpoints were metStudy found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality...

Redding, California, June 01, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, ‘Wheat Protein Market by Type (Vital Wheat Gluten, Protein Isolates, Hydrolyzed Proteins,...

       - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -        - Additional data from ongoing ADG126 clinical program to be...

Regina, SK, May 26, 2022 (GLOBE NEWSWIRE) -- A new $19 million project by Protein Industries Canada and a consortium of companies will help Canadian farmers further improve their substantiality and...

LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented...

Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled,...

Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date Seventeen of 18 patients with follow-up...

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) --...